PI3K inhibitor ACP-319

An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. PI3K inhibitor ACP-319 inhibits PI3K, which prevents the activation of the PI3K/AKT (protein kinase B)-mediated signaling pathway. This results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Check for active clinical trials using this agent.

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More